Covid deaths and systemic adverse effects

58% of coronavirus deaths in August (US data) were people who were vaccinated or boosted Kaiser Family Foundation vice president Cynthia Cox https://www.cdc.gov/vaccines/covid-19/effectiveness-research/protocols.html https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/monitoring.html https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/d6p8-wqjm https://www.washingtonpost.com/politics/2022/11/23/vaccinated-people-now-make-up-majority-covid-deaths/ 58% of coronavirus deaths in August were people who were vaccinated or boosted (people who had completed at least their primary series of vaccines) Therefore 42% coronavirus deaths in August were people who were unvaccinated First time there were more deaths covid deaths in the vaccinated versus the unvaccinated https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5 In September 2021 Vaccinated people, 23% of coronavirus fatalities In January and February 2022 Vaccinated people, 42% of coronavirus fatalities We can no longer say this is a pandemic of the unvaccinated (who conducted the analysis on behalf of the Post) https://www.cdc.gov/mmwr/volumes/71/wr/mm7144a3.htm?s_cid=mm7144a3_w Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years — United States, August 31–October 23, 2022 On August 31, 2022 FDA authorized bivalent, Pfizer-BioNTech and Moderna mRNA encoding the spike protein from original strain of SARS-CoV-2, and from Omicron BA.4 and BA.5 Advisory Committee on Immunization Practices (ACIP) recommended, all persons ≥12 years receive an age-appropriate bivalent mRNA booster dose v-safe a voluntary smartphone-based U.S. safety surveillance system, established by CDC to monitor adverse events after COVID-19 vaccination As of 3rd October, 10 million users https://icandecide.org/press-release/breaking-news-ican-obtains-cdc-v-safe-data/ Vaccine Adverse Event Reporting System (VAERS) Total data, August 31–October 23, 2022 14.4 million received a bivalent Pfizer-BioNTech 8.2 million adults (≥18 years) a bivalent Moderna booster dose v-safe, among the 211,959 registrants (aged ≥12 years) August 31–October 23, 2022 Reported in the week after vaccination Injection site reactions, 60.8% Systemic reactions, 54.8% Fewer than 1% of v-safe registrants reported receiving medical care Vaccine Adverse Event Reporting System (VAERS) 5,542 reports of adverse events after bivalent booster vaccination (≥12 years) 95.5% of reports were nonserious 4.5% were serious events Health care providers and patients can be reassured that adverse events reported after a bivalent booster dose are consistent with those reported after monovalent doses. Relative risk Absolute risk not given Health impacts after COVID-19 vaccination are less frequent and less severe than those associated with COVID-19 illness (2). Relative risk Absolute risk not given This is their Reference 2 Block JP, Boehmer TK, Forrest CB, et al. Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination—PCORnet, United States, January 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022;71:517–23. https://doi.org/10.15585/mmwr.mm7114e1 PMID:35389977 myocarditis; myocarditis or pericarditis; and myocarditis, pericarditis, or MIS, within 7-day or 21-day risk windows after the index date Comparisons between after vaccine and after infection Relative risk Absolute risk not given Review of v-safe Data During August 31–October 23, 2022 211,959 v-safe registrants had a bivalent booster 1,464 (0.7%) were aged 12–17 years 68,592 (32.4%) were aged 18–49 years 59,209 (27.9%) were aged 50–64 years 82.694 (39.0%) were aged ≥65 years Fourth dose 96,241; 45.4% Fifth dose 106,423; 50.2% In the week after receipt of the bivalent booster dose Local injection site reactions 49.7% among aged ≥65 72.9% among aged 18–49 Systemic reactions 43.5% among aged ≥65 67.9% among aged 18–49 Systemic symptoms Fatigue (30.0%–53.1%) Headache (19.7%–42.8%) Myalgia (20.3%–41.3%) Fever (10.2%–26.3%) Reported inability to complete normal daily activities 10.6% among aged ≥65 years 19.8% among aged 18–49 years Receipt of medical care Reported by 0.8% of registrants